← All trials
NCT05895877
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 21, 2021
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2023
- First posted
- Jun 9, 2023
- Last posted
- Jun 9, 2023
- Enrollment
- 351
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Synmosa Biopharma Corp.Lead sponsor
- National Taiwan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.